ArticleDiscover oncology2025
Paraptosis-related classification and risk signature for prognosis prediction and immunotherapy assessment in gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global research landscape and hotspots of paraptosis: a multi-database bibliometric analysis with a focused literature review.Frontiers in oncology · 2026Pooled it
- Integration of Multi-Omics Data To Understand the Multifaceted Role of RAMP1 across Different Cancer Types.Cell biochemistry and biophysics · 2026Review
- Crosstalk Between Autophagy and Paraptosis: A New Frontier in Cancer Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) poses a significant health threat due to its prevalence and poor prognosis. To improve outcomes, there is an urgent need for novel biomarkers. Paraptosis, a recently discovered form of programmed cell death, remains uninvestigated in GC, and understanding its mechanisms could offer new insights. MATERIALS AND
methodsIn our study, we utilized the TCGA-STAD dataset as the training cohort and GSE84433 as the validation cohort to explore the association between paraptosis-related genes and the clinical risk of gastric cancer (GC). Our goals were to analyze the prognostic value and potential biological mechanisms of these genes. We conducted various analyses, including consistent clustering, differential gene expression analysis, enrichment analysis, and immune infiltration analysis. Ultimately, we developed a paraptosis-related risk signature (PRRS) to assess survival prognosis, drug sensitivity, and immune infiltration based on risk classification. The reliability of our findings was further verified through immunohistochemical staining.
resultsOur results revealed distinct subgroups (C1, C2, and C3) among gastric cancer patients through consensus clustering based on 65 paraptosis-related genes. These subgroups exhibited significant variations in survival rates, immunity scores, and immune cell infiltration. We then developed the Paraptosis-Related Risk Score (PRRS) using cox-lasso regression analysis, incorporating genes such as SLCO2A1, VCAN, RAMP1, and MANEAL. The PRRS effectively distinguished between high-risk and low-risk populations. Validation in an independent dataset and immunohistochemical staining confirmed the accuracy of the PRRS. These findings highlight the close relationship between paraptosis and the immune microenvironment of gastric cancer tumors, and demonstrate the PRRS's robust performance in predicting patient survival.
conclusionThis study underscores the link between paraptosis subtypes and changes in the gastric cancer immunotumour microenvironment. We developed and validated the Paraptosis-Related Risk Score (PRRS), which effectively predicts survival, immune infiltration, and drug sensitivity in gastric cancer patients. Our findings enhance the understanding of paraptosis and suggest potential new therapeutic strategies for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.